Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.964
+0.014 (0.71%)
Jan 22, 2025, 1:51 PM EST - Market open
Cocrystal Pharma Employees
Cocrystal Pharma had 12 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,558,500
Market Cap
19.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
COCP News
- 21 days ago - Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide - Benzinga
- 22 days ago - Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 - GlobeNewsWire
- 5 months ago - Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences - GlobeNewsWire
- 5 months ago - CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 9 months ago - Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 9 months ago - Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - GlobeNewsWire
- 10 months ago - Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 11 months ago - Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A - GlobeNewsWire